Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034437 · ClinicalTrials.gov registry record
Immune Response to Cytomegalovirus
A clinical trial of Cytomegalovirus Infections, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT00034437 is a study of Cytomegalovirus Infections that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 20 participants, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00034437, a study of Cytomegalovirus Infections, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate immune responses against cytomegalovirus (CMV). About 80 percent of adults have been exposed to this virus. CMV typically remains dormant (inactive) in the body, causing no problems. In people with immune suppression, however, the virus can become reactivated and cause life-threatening pneumonia. The knowledge gained from this study may be useful in developing ways to improve immune responses to CMV in stem cell transplant recipients. Healthy normal volunteers between 18 and 65 years of age who have been exposed to cytomegalovirus are eligible for this study. Candidates will be screened with a medical history and blood tests. Those enrolled will provide a 30-milliliter (6-tablespoon) blood sample once a week for 4 weeks and a final sample 2 months later. The blood will be used to design a test to detect immune responses against CMV and determine the differences in these responses among healthy individuals.
Conditions Studied
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2002-04 |
| Est. Completion | 2003-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00034437
The ClinicalTrials.gov registry entry for NCT00034437 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (90% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 0 interventions.
NCT00034437 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00034437 about?
NCT00034437 is a clinical study titled "Immune Response to Cytomegalovirus". This study will evaluate immune responses against cytomegalovirus (CMV). About 80 percent of adults have been exposed to this virus. CMV typically remains dormant (inactive) in the body, causing no problems. In people with immune suppression, however, the virus can become reactivated and cause life-...
What is the current status of trial NCT00034437?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2002-04. Estimated completion is 2003-04.
What conditions does trial NCT00034437 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections.
Who is sponsoring clinical trial NCT00034437?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00034437 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
-
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
RECRUITING
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.